Abstract:e14513 Background: Local recurrence of Hepatocellular Carcinoma (HCC) following potentially curative resection or ablation is an inevitable risk. T cells recognizing neoantigens are present in most cancers including HCC and offer a specific and highly immunogenic target for the personalized vaccination as an adjuvant therapy. The purpose of this study is to evaluate the safety and T cell immune response of a personalized neoantigen-based mRNA loaded dendritic cell (DC) vaccine (LK101) combined with regular ablation in patients with HCC (NCT03674073). Methods: Each patient’s fresh tumor biopsy and matched peripheral blood sample were subjected to whole-exome sequencing and RNA-sequencing. Following determination of somatic mutations and gene expression, up to 30 in silico–predicted potential neoantigens were selected with bioinformatic tool. DCs were generated from the monocytes enriched by leukapheresis, followed by transfection with neoantigen-encoding mRNA through electroporation. In total, 7 doses of LK101 were administered at 1.5×107 cells/injection intradermally with 4-dose priming weekly and 3 boosters in 4-week intervals. The primary endpoint of the clinical study was safety, and key secondary endpoints were immunogenicity, overall survival and recurrence. 24 HCC patients at HKLC stage IIa were enrolled 1:1 to ablation control arm and ablation combined with DC (LK101) arm. Results: The study was completed, patients were followed up for a median of 48.4 months and 38.8 months in vaccination arm and control arm. All of adverse events were Grade 1-2. Most frequent treatment-related adverse events are injection site reactions, inclusive of local pain (63.6%), itch (27.3%) and others (27.3%), such as redness and edema. 3 patients in ablation control arm died, whereas all vaccinated patients survived. The 1-year and 2-year recurrence rates in vaccination arm compared with control arm are 18.2%, respectively. LK101 induced neoantigen-specific T cell responses were investigated by ELISpot analysis. Overall, all patients elicited at least one measurable response. Immune responses to 60-90% of neoantigen peptides were seen post vaccination across patients. Both preexisting immune response and De Novo immune response that targeted neoantigens were observed in vaccinated patients. Moreover, both CD4 and CD8 positive effector memory T cells showed the trend of increase, and PD-1 positive T cells reduced in peripheral blood of patients after vaccination. Conclusions: Combination of LK101 with ablation therapy has a manageable safety profile, showing the evidence of immune activation and potential of prolonged survival. In combination with regular ablation, neoantigen based mRNA loaded DC vaccine is a promising immunotherapy for the treatment of HCC. Clinical trial information: NCT03674073 .

A primary study of immunotherapy with carcinoembryonic antigen peptide-pulsed, autologous human cultured dendritic cells in patients with advanced non-small cell lung cancer

Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer

Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer

A First-in-human Study to Evaluate a Personalized Neoantigen-Based Mrna-Loaded Dendritic Cell Vaccine, in Combination with Ablation, in Patients with Hepatocellular Carcinoma.

Efficacy of DC-CIK-based immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer

Safety and Efficacy of Dendritic Cell-Based Immunotherapy (dcvac/luca) Combined with Carboplatin/pemetrexed for Patients with Advanced Non-Squamous Non-Small-cell Lung Cancer Without Oncogenic Drivers

A Prospective Study of the Efficacy of a Combination of Autologous Dendritic Cells, Cytokine-Induced Killer Cells, and Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients

Immunotherapy of Patient with Hepatocellular Carcinoma Using Cytotoxic T Lymphocytes Ex Vivo Activated with Tumor Antigen-Pulsed Dendritic Cells

P3.02c-049 Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrate Enhanced Antitumor Effect Against Lung Cancer

The safety and anti-tumor effect of multiple peptides-pulsed dendritic cells combined with induced specific cytotoxic T lymphocytes for patients with solid tumors

Impact of Dendritic Cells Combining with Cytokine-Induced Killer Cells Synergized Chemotherapy in Patients of Advanced Non-Small Cell Lung Cancer.

Neoantigen-based Personalized DC Vaccine for Lung Cancer: an Update of Translational Study.

A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients

Dendritic cells loaded with apoptotic tumor cells in the treatment of lung cancer

Therapeutic Efficacy of Dendritic Cells Pulsed by Autologous Tumor Cell Lysate in Combination with CIK Cells on Advanced Renal Cell Carcinoma

Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer

Antitumor Effect of Lung Cancer Vaccine with Umbilical Blood Dendritic Cells in Reconstituted Scid Mice

Clinical Effects of Autologous Dendritic Cells Combined with Cytokine-Induced Killer Cells Followed by Chemotherapy in Treating Patients with Advanced Colorectal Cancer: a Prospective Study

Detection of carcino-embryonic antigen-specific cytotoxic lymphocytes and their association with clinical therapy in patients with non-small cell lung carcinoma

Tumor Antigen-Pulsed Dendritic Cell Vaccine for Treatment of Patients with Advanced Malignant Tumor:A Clinical Observation

Effect of dendritic cell immunotherapy on distribution of dendritic cell subsets in non-small cell lung cancer